Scholarlink

Background <p>The renin–angiotensin system (RAS) plays a critical role in vascular homeostasis and inflammation, and its dysregulation has been implicated in the pathophysiology of COVID-19. We investigated the dynamics of RAS peptides and markers of endothelial dysfunction in relation to respiratory disease progression in hospitalized COVID-19 patients.</p> Methods <p>In this single-centre prospective observational study, 155 adult patients with confirmed SARS-CoV-2 infection were enrolled at hospital admission. Plasma levels of renin, angiotensin I (Ang I), angiotensin II (Ang II), angiotensin 1–7 (Ang 1–7), the Ang II/Ang I ratio (as a surrogate of ACE activity), and asymmetric dimethylarginine (ADMA)—a marker of endothelial dysfunction —were measured at baseline (D0) and day 3 (D3). Endothelial injury was further assessed using the Endothelial Activation and Stress Index (EASIX). Patients were stratified by respiratory trajectory using the WHO ordinal scale. Biomarker kinetics were analysed with baseline-adjusted regression models, and 28-day clinical status was evaluated using partial proportional-odds regression.</p> Results <p>Of 155 patients, 89 (57%) experienced worsening respiratory status. These patients exhibited progressive RAS activation with higher renin and Ang I at D3 (<i>p</i> &lt; 0.001), a decline in the Ang II/Ang I ratio (<i>p</i> &lt; 0.001), and a rise in Ang 1–7 (<i>p</i> &lt; 0.001). ADMA and EASIX levels increased in parallel, with significantly higher ADMA in worsening vs. non-worsening patients at D3 (0.72 [0.62–0.87] vs. 0.61 [0.50–0.70] µM/L; <i>p</i> &lt; 0.001). Biomarker trajectories differed according to disease course, with significant interaction terms between baseline values and respiratory deterioration. At 28&#xa0;days, outcomes were associated with renin, Ang I, Ang 1–7, and the Ang II/Ang I ratio, but not with Ang II. Elevated baseline ADMA also independently predicted worse prognosis.</p> Conclusions <p>Worsening respiratory status in COVID-19 is associated with delayed activation of the RAS, a shift toward the alternative Ang 1–7 pathway, and parallel increases in endothelial dysfunction markers. These findings suggest that serial measurements of RAS peptides and ADMA may aid in identifying high-risk phenotypes and inform personalized therapeutic strategies in COVID-19.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Renin–angiotensin system activation and oxidative stress in hospitalized COVID-19 patients: a single-centre prospective observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Davide Eleuteri,
  • Filippo Del Tedesco,
  • Federico Silvia,
  • Caterina Tucciariello,
  • Ersilia Ruggiero,
  • Jacopo Gervasoni,
  • Lavinia Santucci,
  • Aniello Primiano,
  • Martina Petrucci,
  • Ernico Torelli,
  • Rossella Cianci,
  • Diana Giannarelli,
  • Salvatore Lucio Cutuli,
  • Gennaro De Pascale,
  • Giuseppe Bello,
  • Calabrese Maria,
  • Matteo Masullo,
  • Andrea Urbani,
  • Riccardo Di Santo,
  • Massimo Antonelli,
  • Luca Montini,
  • Alessandra Bisanti,
  • Simone Carelli,
  • Paolo De Santis,
  • Valentina Di Gravio,
  • Valentina Giammatteo,
  • Domenico Luca Grieco,
  • Antonio Gullì,
  • Daniel Livanu,
  • Rikardo Xhemalaj,
  • Giovanna Mercurio,
  • Gabriele Ciasca

摘要

Background

The renin–angiotensin system (RAS) plays a critical role in vascular homeostasis and inflammation, and its dysregulation has been implicated in the pathophysiology of COVID-19. We investigated the dynamics of RAS peptides and markers of endothelial dysfunction in relation to respiratory disease progression in hospitalized COVID-19 patients.

Methods

In this single-centre prospective observational study, 155 adult patients with confirmed SARS-CoV-2 infection were enrolled at hospital admission. Plasma levels of renin, angiotensin I (Ang I), angiotensin II (Ang II), angiotensin 1–7 (Ang 1–7), the Ang II/Ang I ratio (as a surrogate of ACE activity), and asymmetric dimethylarginine (ADMA)—a marker of endothelial dysfunction —were measured at baseline (D0) and day 3 (D3). Endothelial injury was further assessed using the Endothelial Activation and Stress Index (EASIX). Patients were stratified by respiratory trajectory using the WHO ordinal scale. Biomarker kinetics were analysed with baseline-adjusted regression models, and 28-day clinical status was evaluated using partial proportional-odds regression.

Results

Of 155 patients, 89 (57%) experienced worsening respiratory status. These patients exhibited progressive RAS activation with higher renin and Ang I at D3 (p < 0.001), a decline in the Ang II/Ang I ratio (p < 0.001), and a rise in Ang 1–7 (p < 0.001). ADMA and EASIX levels increased in parallel, with significantly higher ADMA in worsening vs. non-worsening patients at D3 (0.72 [0.62–0.87] vs. 0.61 [0.50–0.70] µM/L; p < 0.001). Biomarker trajectories differed according to disease course, with significant interaction terms between baseline values and respiratory deterioration. At 28 days, outcomes were associated with renin, Ang I, Ang 1–7, and the Ang II/Ang I ratio, but not with Ang II. Elevated baseline ADMA also independently predicted worse prognosis.

Conclusions

Worsening respiratory status in COVID-19 is associated with delayed activation of the RAS, a shift toward the alternative Ang 1–7 pathway, and parallel increases in endothelial dysfunction markers. These findings suggest that serial measurements of RAS peptides and ADMA may aid in identifying high-risk phenotypes and inform personalized therapeutic strategies in COVID-19.